Skip to content

Women with Benign and Malignant Ovarian Masses- The Demographic Profile, Tumor Markers, and the Effect of these Neoplasms on their Lifestyle.

The Demographic Profile and Tumor Markers in Women Presenting with Benign and Malignant Ovarian Masses and the Effect of these Neoplasms on their Lifestyle. - UG-OM-B/M

Status
Active, not recruiting
Phases
Phase 2
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/03/040749
Enrollment
100
Registered
2022-03-02
Start date
Unknown
Completion date
Unknown
Last updated
2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N74- Female pelvic inflammatory disorders in diseases classified elsewhere

Interventions

None listed

Sponsors

Intramural AIIMS UG Mentorship Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. All patients were diagnosed with a pelvic mass of suspected ovarian origin and were scheduled for surgical intervention. 2. All patients underwent imaging by pelvic ultrasound to document the presence of a malignant ovarian mass.

Exclusion criteria

Exclusion criteria: 1. Women with a previous bilateral oophorectomy. 2. Pregnancy with adnexal masses.

Design outcomes

Primary

MeasureTime frame
1. Evaluation of demographic profile of women presenting with benign and malignant ovarian masses and its impact on the outcome of the patients. 2. Evaluation of HE4 and ROMA as test for predicting for Epithelial ovarian cancer in pre-menopausal and post-menopausal women. Timepoint: 8th month.

Secondary

MeasureTime frame
1. Assessing the impact of ovarian carcinoma on the mental health and psychological well being of patients suffering from epithelial ovarian carcinoma using DASS scale.Timepoint: 10th month.

Countries

India

Contacts

Public ContactDr Nilanchali Singh

AIIMS, New Delhi

nilanchalisingh@gmail.com9811343168

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026